GlassScriptPhysician profile
Harrison Willis Johnson
NPI 1750325437
$3,213.62
in general payments reported to CMS, 2019-2025
33 companies · $21.86 in 2025
The $21.86 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,342 · 2020: $801 · 2021: $662 · 2022: $352 · 2023: $35.03 · 2025: $21.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $56.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $56.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $534.22 | 2019-2022 | |
| Irras USA, INC. | $427.67 | 2019 | |
| Boston Scientific Corporation | $277.36 | 2019-2020 | |
| Emd Serono, INC. | $275.08 | 2020-2021 | |
| Amgen INC. | $146.62 | 2019-2021 | |
| Biogen, INC. | $137.83 | 2019-2022 | |
| Eisai INC. | $136.72 | 2019-2022 | |
| Mdd US Operations, LLC | $122.47 | 2019-2020 | |
| Abbvie INC. | $117.50 | 2021-2023 | |
| Upsher-Smith Laboratories LLC | $106.33 | 2021 | |
| Genzyme Corporation | $91.65 | 2019-2020 | |
| Pfizer INC. | $86.42 | 2019-2022 | |
| Lundbeck LLC | $75.53 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $72.86 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $69.50 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $64.16 | 2021 | |
| Greenwich Biosciences, INC. | $54.64 | 2021 | |
| Neurocrine Biosciences, INC. | $43.83 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $40.72 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $38.02 | 2019 | |
| Ucb, INC. | $35.41 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.86 | 2019 | |
| Lilly USA, LLC | $26.71 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $26.69 | 2021 | |
| Jazz Pharmaceuticals INC. | $23.78 | 2022 | |
| Supernus Pharmaceuticals, INC. | $23.48 | 2019 | |
| Acadia Pharmaceuticals INC | $23.26 | 2019 | |
| Kyowa Kirin, INC. | $22.11 | 2022 | |
| Hollister Incorporated | $21.86 | 2025 | New Image, Premier |
| Adamas Pharmaceuticals, INC. | $17.79 | 2019 | |
| Medtronic, INC. | $17.61 | 2022 | |
| Neurelis, INC. | $14.12 | 2021 | |
| Sunovion Pharmaceuticals INC. | $11.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harrison Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.